This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
Manipal Hospital
Bangalore, Karnataka, India
HealthCare Global Enterprises Limited
Banglore, Karnataka, India
Marthwada Regional Cancer Center & Research Institute
Aurangabad, Maharashtra, India
MOC Cancer Care & Research Centre
Mumbai, Maharashtra, India
HCG NCHRI Cancer Center
Nagpur, Maharashtra, India
HCG Manavata Cancer Centre
Nashik, Maharashtra, India
Apex Wellness Hospital
Nashik, Maharashtra, India
Grant Medical Foundation, Ruby Hall Clinic
Pune, Maharashtra, India
Jehangir Clinical Development Centre Pvt. Ltd
Pune, Maharashtra, India
Sahyadri Speciality Hospital
Pune, Maharashtra, India
...and 3 more locations
Safety: Incidence of adverse events
Time frame: up to approximately 1.5 years
Progression-free survival
Time frame: up to approximately 1.5 years
Overall survival
Time frame: up to approximately 1.5 years
Overall response rate (complete response + partial response)
Time frame: up to approximately 1.5 years
Clinical benefit rate (complete response + partial response + stable disease)
Time frame: up to approximately 1.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.